Korea Pharma한국파마
032300 · KOSDAQ · ₩032300 · 한국파마
- Market cap
- ₩89B
- Enterprise value
- ₩89B
- P/E
- —
- P/B
- 1.2×
- Dividend yield
- 0.0%
- ROE
- −1.3%
- Net margin
- −1.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−45.4% from the high
₩6,350Today: ₩8,050 – ₩8,290₩14,950
Returns
- 1W−3.7%
- 1M+12.8%
- 3M+13.9%
- 6M−30.5%
- YTD−37.2%
- 1Y−39.4%
- Volume today
- 13,311
- 0.1× the 20-day average
- Traded today
- ₩108M
- Listed shares
- 10,906,701
- EPS (12 months)
- −₩86
- Earnings yield −1.1%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 27 of 100 (50 is a normal day for this stock).
- MomentumStrong13.2% over the last month; the price is above its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Korea Pharma stock overview
Korea Pharma (한국파마, KRX: 032300) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops and manufactures prescription pharmaceuticals, with strengths in psychoneurological, digestive, cardiovascular and anti-infective drugs, and also sells products for endocrine, respiratory, anti-inflammatory and diabetes indications. Its shares closed at ₩8,170 on Oct 27, 2026, up 0.74% on the day, giving it a market value of ₩89B.
Key facts
- Market cap
- ₩89B
- Sector
- Biotech & Pharma
- Latest price change
- +0.74%
- As of
- Oct 27, 2026
- Main business
- The company develops and manufactures prescription pharmaceuticals, with strengths in psychoneurological, digestive, cardiovascular and anti-infective drugs, and also sells products for endocrine, respiratory, anti-inflammatory and diabetes indications.
Quick answers about Korea Pharma
- What does Korea Pharma do?
- The company develops and manufactures prescription pharmaceuticals, with strengths in psychoneurological, digestive, cardiovascular and anti-infective drugs, and also sells products for endocrine, respiratory, anti-inflammatory and diabetes indications. It offers contract manufacturing (CMO) for tablets, capsules, solutions, ointments and lotions, and exports products to about 17 countries. The company also operates research centers in Daegu and Uiwang and licenses out its formulation technology to domestic and overseas pharmaceutical firms.
- What is the market cap of Korea Pharma?
- The market capitalisation of Korea Pharma was ₩89B at the close on Oct 27, 2026.
- Who are the largest shareholders of Korea Pharma?
- According to the latest official filings, the largest reported holders are Park Eun-hee (64.09%, as of Aug 4, 2026); Park Jae-don (25.12%, as of Nov 22, 2024).
- When is the next earnings report from Korea Pharma?
- Korean companies rarely announce results dates in advance. Based on when Korea Pharma filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
Company profile
The company develops and manufactures prescription pharmaceuticals, with strengths in psychoneurological, digestive, cardiovascular and anti-infective drugs, and also sells products for endocrine, respiratory, anti-inflammatory and diabetes indications. It offers contract manufacturing (CMO) for tablets, capsules, solutions, ointments and lotions, and exports products to about 17 countries. The company also operates research centers in Daegu and Uiwang and licenses out its formulation technology to domestic and overseas pharmaceutical firms.
Written by AI from the company's latest annual report.
- Korean name
- 한국파마
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 박은희
- Founded
- Dec 1985
- Listed
- Aug 2020
- Listed shares
- 10,906,701
- Fiscal year ends
- Month 12
- Website
- koreapharma.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Buyback trust contract signedOct 2, 2026
- Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) After Issuance and Before MaturityAug 28, 2026
- Half-year report (Jun 2026)Aug 13, 2026
- 5%+ holding reportAug 4, 2026
- 5%+ holding reportJul 24, 2026
Titles in Korean until English translations are added.
Also known as: Korea Pharma / 한국파마 / 032300 / KRX:032300
Source: KRX statistical information